After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.

Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.

The FDA-cleared ShortCut leaflet modification device has been linked to positive real-world outcomes.

A vast majority of patient deaths in the first year after TAVR have nothing to do with heart health. Could care teams be doing more to identify high-risk patients? 

Philippe Généreux, MD, presented updated findings from one of cardiology's most closely watched trials at New York Valves 2026. 

TAVR was associated with early benefits for women. After five years, however, outcomes were comparable across the board.

A failed TAVR procedure has left one family unsure about where things went wrong. 

Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific. 

All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.